scholarly journals Antiangiogenic Therapy for Hepatocellular Carcinoma

10.5772/66503 ◽  
2017 ◽  
Author(s):  
Kosuke Kaji ◽  
Hitoshi Yoshiji
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiangiogenic Therapy

scholarly journals The Role of Endoglin in Hepatocellular Carcinoma

2021 ◽  
Vol 22 (6) ◽  
pp. 3208
Author(s):  
Kuo-Shyang Jeng ◽  
I-Shyan Sheen ◽  
Shu-Sheng Lin ◽  
Chuen-Miin Leu ◽  
Chiung-Fang Chang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Diseases ◽  
Transforming Growth Factor ◽  
Antiangiogenic Therapy ◽  
Transforming Growth Factor Β ◽  
Postoperative Recurrence ◽  
Transmembrane Glycoprotein ◽  
Early Progression

Endoglin (CD105) is a type-1 integral transmembrane glycoprotein and coreceptor for transforming growth factor-β (TGF-β) ligands. The endoglin/TGF-β signaling pathway regulates hemostasis, cell proliferation/migration, extracellular matrix (ECM) synthesis and angiogenesis. Angiogenesis contributes to early progression, invasion, postoperative recurrence, and metastasis in hepatocellular carcinoma (HCC), one of the most widespread malignancies globally. Endoglin is overexpressed in newly formed HCC microvessels. It increases microvessel density in cirrhotic and regenerative HCC nodules. In addition, circulating endoglin is present in HCC patients, suggesting potential for use as a diagnostic or prognostic factor. HCC angiogenesis is dynamic and endoglin expression varies by stage. TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise.

scholarly journals Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

2011 ◽  
Vol 5 (3) ◽  
pp. 177-184 ◽  
Author(s):  
Justin B. Wenger ◽  
Napoleon Santos ◽  
Yanxia Liu ◽  
Jennifer Dallas ◽  
Sukanthini Subbiah ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiangiogenic Therapy ◽  
Effective Combination

Rapamycin in patients with advanced hepatocellular carcinoma progressing on prior antiangiogenic therapy.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 356-356
Author(s):  
Mohamed Bouattour ◽  
Johanna Wassermann ◽  
Chantal Dreyer ◽  
Valérie Vilgrain ◽  
Valerie Paradis ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Stable Disease ◽  
Tumor Response ◽  
Antiangiogenic Therapy ◽  
Mtor Inhibitors ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
Disease Stabilization ◽  
Heavily Pretreated ◽  
Grade 3

356 Background: PI3K/Akt/mTOR is a critical survival pathway in hepatocellular carcinoma (HCC) often correlated with poor prognosis. Rapamycin (sirolimus) and its analogue everolimus, are specific mTOR inhibitors that showed promising antitumor activity in preclinical models and clinical cases of HCC Aims: To evaluate the safety and efficacy of rapamycin in patients (pts) with advanced HCC after failure or intolerance to prior antiangiogenic therapy Methods: In this retrospective cohort, we analyzed consecutive patients with progressive HCC after 1 to 3 lines of treatment including at least sorafenib. All pts received oral rapamycin at 20 to 30 mg once a week. Adverse events (AEs) were assessed using NCI-CTCAE v3.0, and tumor response was evaluated according to RECIST criteria. Results: Nine patients (F/M: 1/8) with compensated liver cirrhosis (Child A, n = 6; Child B7, n = 2) or no cirrhosis (n=1) and histologically proven HCC were included in this study. Overall, therapy with rapamycin was well tolerated. Most common toxicities were asthenia (grade 1-2: 5 pts) anaemia (all grade: 5 pts; grade 3: 2 pts ) and thrombocytopenia (grade 1-2: 2 pts). Liver function deterioration was observed in 2 pts with advanced cirrhosis (Child B7). Radiological evaluation was available in 6 pts. No objective tumor response was observed however stable disease ≥ 3 months was observed in 4 cases. Moreover, 2 pts showed stable disease at 6 months. Prolonged stabilization under rapamycin was observed in pts who were previously controlled at least for 6 months with sorafenib. Rapamycin was discontinued due to disease progression in 7/8 pts, toxicity in 1/8 pts. One pt shows ongoing long-lasting disease stabilization (8 + months). Conclusions: Rapamycin displayed an acceptable safety profile and may achieved disease stabilization in patients with heavily pretreated advanced HCC.

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4092-4092 ◽  
Author(s):  
Mairead Geraldine McNamara ◽  
Lisa W Le ◽  
Anne M Horgan ◽  
Alex Aspinall ◽  
Kelly W Burak ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Antiangiogenic Therapy ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

2006 ◽  
Vol 242 (2) ◽  
pp. 151-167 ◽  
Author(s):  
Roberta Pang ◽  
Ronnie T.P. Poon
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiangiogenic Therapy
Sign in / Sign up

Export Citation Format

Share Document